Overview

A Phase I Study of TAS-102 in Solid Tumors

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.

Phase:

Phase 1

Details

Lead Sponsor:

Taiho Pharmaceutical Co., Ltd.

Treatments:

Trifluridine